145 related articles for article (PubMed ID: 17156828)
1. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer.
Yoshida Y; Kurokawa T; Sawamura Y; Shinagawa A; Okazawa H; Fujibayashi Y; Kotsuji F
Gynecol Oncol; 2007 Mar; 104(3):764-6. PubMed ID: 17156828
[TBL] [Abstract][Full Text] [Related]
2. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
4. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
5. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
Tsujikawa T; Okazawa H; Yoshida Y; Mori T; Kobayashi M; Tsuchida T; Fujibayashi Y
Ann Nucl Med; 2008 Jan; 22(1):73-7. PubMed ID: 18250990
[TBL] [Abstract][Full Text] [Related]
6. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
[TBL] [Abstract][Full Text] [Related]
7. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
[TBL] [Abstract][Full Text] [Related]
8. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
9. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
11. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
12. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
14. Non-
Kalshetty A; Basu S
PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
[TBL] [Abstract][Full Text] [Related]
15. A Rare Case of Primary Endometrial Hepatoid Adenocarcinoma on 18F-FDG PET/CT.
Yin H; Hu Y; Xiu Y; Luo R; Shi H
Clin Nucl Med; 2019 Jul; 44(7):e425-e427. PubMed ID: 30985410
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of 16α-[18F]-Fluoro-17β-Estradiol PET as a Biomarker of Progestin Therapy Resistance in Patients With Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer.
Yamada S; Tsuyoshi H; Tsujikawa T; Okazawa H; Yoshida Y
Clin Nucl Med; 2019 Jul; 44(7):574-575. PubMed ID: 31107747
[TBL] [Abstract][Full Text] [Related]
17. Endometriosis Under Estradiol Stimulation Imaged Using 18F-FDG and Its Control After Estradiol Cessation and Progesterone Hormonal Replacement.
Arsenault F; Turcotte É
Clin Nucl Med; 2016 Mar; 41(3):e143-5. PubMed ID: 26505859
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET in carcinoma of the uterine cervix with endometrial extension.
Hope AJ; Saha P; Grigsby PW
Cancer; 2006 Jan; 106(1):196-200. PubMed ID: 16302228
[TBL] [Abstract][Full Text] [Related]
19. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
20. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
